Erika J. Nachman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Erika J. Nachman has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Robert A. Britton
Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, USA
3 shared publications Sara C. Di Rienzi
Department of Neuroscience and Cell Biology, Rutgers University, Piscataway, USA
3 shared publicationsA. Kyle B. Ardis
Department of Molecular Virology and Microbiology, Baylor College of Medicine
2 shared publicationsClare M. Robertson
Department of Molecular Virology and Microbiology, Baylor College of Medicine
2 shared publicationsColleen K. Ardis
Department of Molecular Virology and Microbiology, Baylor College of Medicine
2 shared publicationsEva C. Preisner
Department of Molecular Virology and Microbiology, Baylor College of Medicine
2 shared publications
Latest Publications
- 10 November 2026
- Published by Springer Nature in Nature Reviews Microbiology
- p. 1-15
The small intestine microbiome: composition, host interactions and therapeutic potential
The human microbiome, the collection of microorganisms that inhabit the human body, has been extensively studied over the past two decades and has been shown to play a critical part in health and disease. These research efforts renewed interest in developing microbial therapeutics to promote human health and treat disease. However, the vast majority of human gut microbiome research has been focused on fecal microbial strains and communities, leaving most of the gastrointestinal tract understudied. The dynamic environment of the small intestine provides distinct opportunities for microorganisms to interact with the host and diet. In this Review, we discuss the current state of research on the microbiome of the small intestine, how interactions between the small intestine and its microbiome influence host physiology, and we posit that small intestinal microorganisms are a unique source of novel therapeutics for treating human disease. Next-generation microbial therapeutics that emerge from the small intestinal microbiome are anticipated to be relevant to improving small intestinal diseases as well as systemic human health.
- 10 November 2026
- Published by Springer Nature in Nature Reviews Microbiology
- p. 1-15
The small intestine microbiome: composition, host interactions and therapeutic potential
The human microbiome, the collection of microorganisms that inhabit the human body, has been extensively studied over the past two decades and has been shown to play a critical part in health and disease. These research efforts renewed interest in developing microbial therapeutics to promote human health and treat disease. However, the vast majority of human gut microbiome research has been focused on fecal microbial strains and communities, leaving most of the gastrointestinal tract understudied. The dynamic environment of the small intestine provides distinct opportunities for microorganisms to interact with the host and diet. In this Review, we discuss the current state of research on the microbiome of the small intestine, how interactions between the small intestine and its microbiome influence host physiology, and we posit that small intestinal microorganisms are a unique source of novel therapeutics for treating human disease. Next-generation microbial therapeutics that emerge from the small intestinal microbiome are anticipated to be relevant to improving small intestinal diseases as well as systemic human health.
- 9 November 2026
- Published by Wiley in Journal of Surgical Oncology
Therapeutic Targeting of the Cancer Microbiome and Metabolome: Ongoing Trials and Future Directions for the Surgical Oncologist
The role of the human microbiome in cancer development, progression, and response to therapy has moved from correlative curiosity to demonstrated impact on tumor biology. This represents a critical factor for surgical oncologists as they not only resect these tumors, but also direct perioperative antimicrobial exposure and increasingly co‐manage neoadjuvant and surveillance pathways in which microbial state may predict and modify response. This review summarizes the basis for therapeutic modulation of the cancer microbiome and metabolome in a contemporary clinical‐trial landscape across four broad strategies: additive (fecal microbiota transplantation, defined consortia, and live biotherapeutic products), subtractive (targeted antimicrobials), dietary and metabolome‐directed interventions, and engineered or next‐generation platforms. Particular attention is given to subtractive approaches in colon and rectal cancer and to the underexplored perioperative interface between the microbiome and surgical outcomes such as anastomotic leak. We outline the principal methodological and translational obstacles, including low‐biomass contamination, causal inference, unintended antibiotic effects, and product standardization. Looking ahead, we propose roles for surgeons across the care continuum, from biospecimen stewardship and trial referral to integration of microbiome and circulating tumor DNA signals in surveillance.
- 9 November 2026
- Published by Wiley in Journal of Surgical Oncology
Therapeutic Targeting of the Cancer Microbiome and Metabolome: Ongoing Trials and Future Directions for the Surgical Oncologist
The role of the human microbiome in cancer development, progression, and response to therapy has moved from correlative curiosity to demonstrated impact on tumor biology. This represents a critical factor for surgical oncologists as they not only resect these tumors, but also direct perioperative antimicrobial exposure and increasingly co‐manage neoadjuvant and surveillance pathways in which microbial state may predict and modify response. This review summarizes the basis for therapeutic modulation of the cancer microbiome and metabolome in a contemporary clinical‐trial landscape across four broad strategies: additive (fecal microbiota transplantation, defined consortia, and live biotherapeutic products), subtractive (targeted antimicrobials), dietary and metabolome‐directed interventions, and engineered or next‐generation platforms. Particular attention is given to subtractive approaches in colon and rectal cancer and to the underexplored perioperative interface between the microbiome and surgical outcomes such as anastomotic leak. We outline the principal methodological and translational obstacles, including low‐biomass contamination, causal inference, unintended antibiotic effects, and product standardization. Looking ahead, we propose roles for surgeons across the care continuum, from biospecimen stewardship and trial referral to integration of microbiome and circulating tumor DNA signals in surveillance.
- Open Access
- 6 January 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (1) , e0285825
Erratum for Nachman et al., “Increased fungal burden in the gastrointestinal tract of brain-dead organ donors”
- 6 January 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (1) , e0285825
Open AccessErratum for Nachman et al., “Increased fungal burden in the gastrointestinal tract of brain-dead organ donors”
- Open Access
- 5 August 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (8) , e0334124
Increased fungal burden in the gastrointestinal tract of brain-dead organ donors
Approximately 3% of organ transplant recipients will be diagnosed with an invasive fungal infection (IFI), with 10%–47% being fatal. The source of IFI is typically not known, but Candida spp. cause the majority of IFI cases. We obtained intestines from two types of organ donors, brain-dead (BD) ( n = 7) and donation after circulatory death (DCD) ( n = 5), to sample microbes from the mucosal surface and the lumen. BD donors were parenterally fed and treated with corticosteroids in the days before procurement, whereas DCD donors were enterally fed and not given corticosteroids. We found fungi present in 81% of BD donor samples compared to 31% of DCD donor samples. The fungal load was significantly increased in most of the intestinal sites in BD donor samples over DCD donor samples. We recovered 12 isolates of Candida albicans , 10 isolates of Nakaseomyces glabratus, and one isolate of Candida tropicalis from the human intestine of nine organ donors. Sequence analysis revealed a high prevalence of gene families associated with virulence and drug resistance, the latter of which was corroborated by antifungal resistance testing. Overall, this study provides evidence of increased fungal presence in BD donors compared to DCD donors, which suggests that corticosteroid administration and parenteral feeding strategies of BD donors may impact the burden of IFI in transplant recipients. IMPORTANCE: Invasive fungal infections pose a significant risk to organ donor recipients, and the sources of these fungal infections are mostly unknown. Our study investigated fungal differences in the gastrointestinal tract between two types of organ donors: brain-dead and donation by circulatory death, for the first time. We found that brain-dead donors had a significant increase in the frequency and abundance of fungi throughout the gastrointestinal tract. We speculate that differences in care, such as corticosteroid administration and feeding methods before organ procurement, may begin to explain the difference in fungal presence between the donors. We propose further studies into the administration of steroids and delivery of nutrients to organ donors before procurement to impact fungal load and reduce life-threatening invasive fungal infections in the recipients.
- 5 August 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (8) , e0334124
Open AccessIncreased fungal burden in the gastrointestinal tract of brain-dead organ donors
Approximately 3% of organ transplant recipients will be diagnosed with an invasive fungal infection (IFI), with 10%–47% being fatal. The source of IFI is typically not known, but Candida spp. cause the majority of IFI cases. We obtained intestines from two types of organ donors, brain-dead (BD) ( n = 7) and donation after circulatory death (DCD) ( n = 5), to sample microbes from the mucosal surface and the lumen. BD donors were parenterally fed and treated with corticosteroids in the days before procurement, whereas DCD donors were enterally fed and not given corticosteroids. We found fungi present in 81% of BD donor samples compared to 31% of DCD donor samples. The fungal load was significantly increased in most of the intestinal sites in BD donor samples over DCD donor samples. We recovered 12 isolates of Candida albicans , 10 isolates of Nakaseomyces glabratus, and one isolate of Candida tropicalis from the human intestine of nine organ donors. Sequence analysis revealed a high prevalence of gene families associated with virulence and drug resistance, the latter of which was corroborated by antifungal resistance testing. Overall, this study provides evidence of increased fungal presence in BD donors compared to DCD donors, which suggests that corticosteroid administration and parenteral feeding strategies of BD donors may impact the burden of IFI in transplant recipients. IMPORTANCE: Invasive fungal infections pose a significant risk to organ donor recipients, and the sources of these fungal infections are mostly unknown. Our study investigated fungal differences in the gastrointestinal tract between two types of organ donors: brain-dead and donation by circulatory death, for the first time. We found that brain-dead donors had a significant increase in the frequency and abundance of fungi throughout the gastrointestinal tract. We speculate that differences in care, such as corticosteroid administration and feeding methods before organ procurement, may begin to explain the difference in fungal presence between the donors. We propose further studies into the administration of steroids and delivery of nutrients to organ donors before procurement to impact fungal load and reduce life-threatening invasive fungal infections in the recipients.